Recent Updates
Recently added Catalysts
OCGN Negative Sentiment Score: 20/100

OCUGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Ocugen, Inc. and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Ocugen, Inc. filed in the U.S. District Court for the Eastern District of Pennsylvania. The lawsuit pertains to claims made by investors who purchased Ocugen securities between May 8, 2020, and April 1, 2024. The complaint alleges that Ocugen failed to disclose material misstatements regarding its financial performance and internal controls, which misled investors about the company's business conditions. Investors have until June 10, 2024, to apply to be appointed as lead plaintiffs.

Market Sentiment Analysis

CONCERNS & RISKS

  • A class action lawsuit has been filed against Ocugen, Inc. for allegedly making false and misleading statements.
  • The complaint states that Ocugen's financial statements were materially misstated and lacked adequate internal controls.
  • Investors are encouraged to contact the law firm for potential claims, suggesting significant investor dissatisfaction.

Full Press Release Details

NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN) in the United States District Court for the Eastern District of Pennsylvania on behalf of all persons and entities who purchased or otherwise acquired Ocugen securities between May 8, 2020 and April 1, 2024, both dates inclusive (the “Class Period”). Investors have until June 10, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
According to the filed complaint, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Ocugen’s financial statements from May 8, 2020 to the present were materially misstated; (2) Ocugen did not have adequate internal controls; and (3) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.
If you purchased or otherwise acquired Ocugen shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Frequently Asked Questions

What is the lawsuit against Ocugen about?

The lawsuit claims Ocugen made misleading statements and misrepresented financial data.

Who can participate in the Ocugen class action?

Any individual or entity that purchased Ocugen securities from May 8, 2020, to April 1, 2024.

When is the deadline to apply as lead plaintiff?

The deadline to apply is June 10, 2024.

How can I contact the law firm regarding the lawsuit?

Contact Bragar Eagel & Squire via email or phone as provided in the announcement.

Is there a cost to participate in the lawsuit?

No, there is no cost or obligation to participate in the lawsuit.

Last updated: Apr 12, 2024